Shares of ProMetic Life Sciences Inc. (TSE:PLI) were up 1.6% during mid-day trading on Monday . The company traded as high as C$1.29 and last traded at C$1.27. Approximately 776,376 shares changed hands during trading, a decline of 22% from the average daily volume of 994,542 shares. The stock had previously closed at C$1.25.

A number of analysts have recently issued reports on PLI shares. Royal Bank of Canada dropped their price objective on shares of ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating on the stock in a research note on Wednesday, August 16th. National Bank Financial decreased their price target on shares of ProMetic Life Sciences from C$2.50 to C$2.00 and set a “sector perform” rating for the company in a research report on Wednesday, November 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of ProMetic Life Sciences in a research report on Monday, November 20th. Finally, TD Securities decreased their price target on shares of ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating for the company in a research report on Wednesday, August 16th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of C$3.50.

In related news, insider Jonathan Booth purchased 75,000 shares of the firm’s stock in a transaction dated Friday, October 6th. The stock was acquired at an average price of C$1.21 per share, with a total value of C$90,750.00. Insiders have bought 86,075 shares of company stock valued at $108,051 in the last three months.

TRADEMARK VIOLATION NOTICE: This piece was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at

ProMetic Life Sciences Company Profile

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with's FREE daily email newsletter.